Temasek-owned Nurasa has teamed up with UK-based New Wave Biotech to address the significant challenge of scaling food-tech innovations from the lab to market. This partnership integrates New Wave Biotech’s bioprocess simulation tools into Nurasa’s ecosystem, enabling companies to predict production costs, yields, and environmental impacts before committing to large-scale investments.
The collaboration is set to enhance Singapore’s role as a hub for sustainable food technologies, tackling high capital costs and scale-up failures that often hinder progress. By combining digital modelling with pilot facilities and market access across Asia, Nurasa aims to reduce risks and accelerate the commercialisation of resilient, sustainable food supply chains.
New Wave Biotech’s Bioprocess Foresight platform will allow companies within Nurasa’s network to virtually test thousands of downstream processing scenarios. This includes automated techno-economic analysis and life-cycle assessment functions, providing clear insights into cost, yield, and environmental trade-offs. The software has demonstrated its ability to cut physical experiments by up to 90% and halve unit costs, offering a clearer path to market for ingredient companies.
Samson Lee, Strategic Partnerships Manager at Nurasa, highlighted Singapore’s growing position as a hub for scalable, sustainable nutrition. He stated, “Integrating New Wave Biotech’s bioprocess simulation capabilities into our platform strengthens our ability to guide both startups and corporates towards commercially viable production.”
Zoe Yu Tung Law, Co-Founder and CEO of New Wave Biotech, added, “Our platform predicts technical outcomes and contextualises them through TEA and LCA, giving teams clear, data-driven insight at every stage of development.”
This partnership aims to strengthen the commercial pathway for sustainable nutrition and biomanufactured ingredients across Asia and Europe, linking digital modelling with real-world scale-up environments and market opportunities.
